Summary: The recent development of vaccines prophylactic against human papillomavirus (HPV) infection has the potential to reduce the incidence of cervical cancer globally by up to 70% over the next 40 years, if universal immunization is adopted. As these prophylactic vaccines do not alter the natural history of established HPV infection, immunotherapies to treat persistent HPV infection and associated precancers would be of benefit to assist with cervical cancer control. Efforts to develop immuno-therapeutic vaccines have been hampered by the relative non-immunogenicity of HPV infection, by immunoregulatory processes in skin, and by subversion of immune response induction and immune effector functions by papillomavirus proteins. This review describes HPV-specific immune responses induced by viral proteins, their regulation by host and viral factors, and highlights some conclusions from our own recent research. © 2010 John Wiley & Sons A/S.
CITATION STYLE
Bhat, P., Mattarollo, S. R., Gosmann, C., Frazer, I. H., & Leggatt, G. R. (2011). Regulation of immune responses to HPVinfection and during HPV-directed immunotherapy. Immunological Reviews, 239(1), 85–98. https://doi.org/10.1111/j.1600-065X.2010.00966.x
Mendeley helps you to discover research relevant for your work.